APWC Q3 Revenue Surges 26% YoY, But EPS Remains Subdued at $0.03

What happened

APWC reported Q3 2026 revenue of $161.7 million, up 18% sequentially and 26% year-over-year, signaling stronger demand momentum after Q1's sequential dip. Quarterly EPS was $0.03, a 200% sequential improvement from Q2 but still below Q1's $0.10 that included a one-off investment gain. The company did not disclose gross margin, operating cash flow, or inventory levels in the press release, leaving key thesis test metrics unresolved. Management framed the results as continued recovery, but the lack of operating detail makes it impossible to verify whether margin durability and cash conversion are improving. This revenue print is directionally supportive but does not yet satisfy the Q3 2026 conditions required to upgrade from WAIT.

Implication

The strong revenue growth increases the probability that Thailand public-sector demand is translating into orders, but without margin data it is premature to conclude that competitive pressures have eased. EPS of $0.03 annualizes to roughly $0.12 per share, which would support only a modest valuation uplift even at the current depressed multiple. Investors should not confuse sequential revenue acceleration with durable earnings power, especially given the company's history of thin margins and one-off gains. The critical next step is the detailed Q3 6-K filing, which should reveal gross margin, operating cash flow, inventory, and any disclosures on rights-offering capital deployment. Until that filing provides evidence that margin stays above 7.5% and operating cash flow exceeds $5 million, the stock is not compelling enough to warrant a ratings change from WAIT.

Thesis delta

The Q3 revenue beat modestly increases confidence that demand is recovering, but the EPS figure does not prove margin durability because it remains below Q1's level and no margin detail was provided. The original thesis required Q3 gross margin above 7.5% and operating cash flow above $5 million to justify an upgrade, and those metrics are still unknown. Therefore the WAIT rating remains appropriate, with a modest tilt toward the bull scenario if subsequent filings confirm operating leverage.